STOCK TITAN

Plandai Biotechnology Inc - PLPL STOCK NEWS

Welcome to our dedicated news page for Plandai Biotechnology (Ticker: PLPL), a resource for investors and traders seeking the latest updates and insights on Plandai Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Plandai Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Plandai Biotechnology's position in the market.

Rhea-AI Summary
Plandai Biotechnology, Inc. announces the rescission of a material definitive agreement with Good Salt, LLC due to the failure of consideration. The agreement, initially entered into on May 16, 2023, outlined the terms for the acquisition of the Company. Plandai will evaluate its options moving forward and exploring alternative opportunities for growth and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
partnership
-
Rhea-AI Summary
ByoPlanet, a subsidiary of Plandai Biotechnology, has established a one-year distribution agreement with Merck Animal Health to distribute Merck's Armatrex antimicrobial solution in the animal health market. The partnership aims to provide customers with advanced antimicrobial solutions and leverage the strengths of both companies. Armatrex offers a comprehensive solution to combat harmful pathogens and protect animals from diseases. ByoPlanet will be responsible for distribution and marketing, while Merck Animal Health brings its reputation for excellence in animal health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
Plandai Biotechnology, Inc. announces the completion of a share exchange agreement with ByoPlanet. ByoPlanet will become a wholly-owned subsidiary of PLPL. Rick O'Shea, CEO of ByoPlanet, will become CEO of Plandai.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
Plandai Biotechnology Inc

OTC:PLPL

PLPL Rankings

PLPL Stock Data

236.87k
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
London

About PLPL

plandaã­ biotechnology, inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. it is developing phytofare catechin complex, a botanical extract derived from green tea harvested in the senteeko tea estate in mpumalanga, south africa; and phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, artemisia, and cannabis. the company also produces and sells timber and agricultural products from its farm and tea estate holdings in south africa. plandaã­ biotechnology, inc. is based in london, the united kingdom.